Large-cap health care company United Therapeutics has moved -0.1% this overnight, reaching $239.98 per share. In contrast, the average analyst target price for the stock is $286.96.
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is based in the United States.
What to Consider if You Are Thinking of Buying United Therapeutics:
-
United Therapeutics has moved -13.0% over the last year.
-
UTHR has a forward P/E ratio of 10.9 based on its EPS guidance of 21.97.
-
Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 5.2%.
-
The company has a price to earnings growth (PEG) ratio of 1.26.
-
Its Price to Book (P/B) ratio is 1.97
United Therapeutics Has Irregular Cash Flows
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 955,500 | 191,200 | 764,300 | 15.16 |
| 2022 | 802,500 | 138,800 | 663,700 | 39.02 |
| 2021 | 598,200 | 120,800 | 477,400 | -31.45 |
| 2020 | 755,700 | 59,300 | 696,400 | 339.89 |
| 2019 | -206,600 | 83,700 | -290,300 | -148.87 |
| 2018 | 778,400 | 184,400 | 594,000 |
United Therapeutics's free cash flows have a decent average of $484.25 Million over the last 6 years, but they are highly variable since their coefficient of variability is 508.5%. The compounded average growth rate over this period is 4.3%.
